Famous Patents
In 1879, Auguste Bartholdi received design patent number 11,023 titled "Design for a Statue". It was for the Statue of Liberty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7402591 | Analgesic compositions containing buprenorphine An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the r... | 07/22/2008 |
| 7255882 | Enkephalinase inhibitor and GABA precursor loading as anti-anxiety compositions Benzodiazepine withdrawal induced anxiety is treated by administration of an enkephalinase inhibitor, and a gamma-aminobutyric acid (“GABA”) precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter functi... | 08/14/2007 |
| 7108871 | Methods of treatment using a soya extract A soya extract having a content of glucoside isoflavones of at least 13% by weight and a content of 0.6 to 1.5 parts by weight of group 3 soya saponins per 1 part by weight of glucoside isoflavones. Also, pharmaceutical compositions containing this extract and metho... | 09/19/2006 |
| 7074833 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprisi... | 07/11/2006 |
| 7005452 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent ... | 02/28/2006 |
| 6995169 | Analgesic compositions containing buprenorphine An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the r... | 02/07/2006 |
| 6828349 | Treatment of addiction and addiction-related behavior The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a mammal suffering from substance addiction. The method includes administering to a mammal an effective amount of gamma vinylGABA... | 12/07/2004 |
| 6627631 | Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of alcoholism. Said substances are administered preferably in a continuos and controlled manner. The pharmaceutical administration form enables controlled ... | 09/30/2003 |
| 6617361 | Behavior chemotherapy A protocol for prevention of Alzheimer's disease onset is described. The protocol involves stimulating the implicit memory, followed by continuing such stimulation in conjunction with psychological treatments followed by continuing said stimulation of the... | 09/09/2003 |
| 6608064 | Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorde... | 08/19/2003 |
| 6593367 | Treatment of addiction and addiction-related behavior The present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to a combination of abused drugs. The method includes administering to the mammal an effective amount of gamma vinylGABA (GVG) or a pharma... | 07/15/2003 |
| 6541520 | Treatment of addiction and addiction-related behavior The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a mammal suffering from substance addiction. The method includes administering to a mammal an effective amount of gamm... | 04/01/2003 |
| 6503950 | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms A triple drug, pharmaceutical kit, composition, and method of treatment containing a combination of effective amounts of at least one anxiolytic agent, at least one centrally acting alpha antiadrenergic agent, and at least one central nervous system stimu... | 01/07/2003 |
| 6495155 | Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular inje... | 12/17/2002 |
| 6492369 | Therapeutic agents for drug dependence A method for preventing or treating drug dependence comprising administering to a human in need thereof a pharmaceutically effective amount of a 1,4-(diphenylalkyl)piperazine compound represented by the following formula [I] or a pharmaceutically acceptab... | 12/10/2002 |
| 6352984 | Olanzapine-N-oxide compositions and methods Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzap... | 03/05/2002 |
| 6333357 | Behavior chemotherapy A protocol for permanent modification of behavior and elimination of undesired habits is described. The protocol involves stimulating the implicit memory, followed by continuing such stimulation in conjunction with psychological treatments followed by con... | 12/25/2001 |
| 6306425 | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner... | 10/23/2001 |
| 6288047 | Lipid-based immune modulator composition A method of treating an individual with an immune system with decreased activity by administering an effective amount of a lipid preparation derived from a natural source and enriched to contain at least 10% (w/w) phosphatidic acid (PA) is disclosed.... | 09/11/2001 |
| 6245360 | Nutritional supplement A single entity product is provided for administration to persons being treated for nutritional deficiencies associated with addiction to alcohol, wherein the product is an extended-release multivitamin with minerals and trace elements in beneficial dose ... | 06/12/2001 |
| 6204284 | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies The invention is a method of treatment for the relief of an addictive, compulsive disorder which comprises the administration to a human or animal suffering from such a disorder an effective amount of the compound of the formula: ##STR1## wherein R i... | 03/20/2001 |
| 6197827 | Nicotine addiction treatment The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoki... | 03/06/2001 |
| 6159963 | Method for treating substance abuse The invention provides a method for treating substance abuse comprising administering an effective amount of olanzapine or pharmaceutically acceptable salt thereof to a patient in need thereof.... | 12/12/2000 |
| 6121259 | Olanzapine-N-oxide compositions and methods Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzap... | 09/19/2000 |
| 6120806 | Oral formulations for controlled release of alcohol deterrents An oral controlled release dosage form for cyanamide whereby a portion of a cyanamide dose administered to a patient remains transiently partitioned within encapsulating material, thereby retarding metabolism of the total administered cyanamide dose, is d... | 09/19/2000 |
| 6068981 | Marking of orally ingested products A method of monitoring a therapeutic regimen in an animal, the method involving a) providing to the animal a therapeutic compound and a detectable compound that passes into the bloodstream, excretory system, or other tissue or body fluid in detectable for... | 05/30/2000 |
| 6051564 | Phosphatidic acid-comprising compositions The invention is to a method for the treatment of withdrawal symptoms selected from the group consisting of nausea, sweating, shaking, substance craving and hot flushes.... | 04/18/2000 |
| 6017884 | Method for treating acute hepatic failure The present invention provides a novel method for treating acute hepatic failure comprising administering a therapeutically effective amount of human growth hormone (hGH) to a patient suffering from the acute hepatic failure as well as a novel therapeutic... | 01/25/2000 |
| 6001848 | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele Disclosed are dopamine agonist and opioidergic compositions and methods for their use in the treatment of alcoholism. The invention discloses compounds and therapeutic kits useful in the treatment of alcoholics having the A1 allele of the dopamine recepto... | 12/14/1999 |
| 5958962 | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence The invention relates to a method of treating alcoholism and alcohol dependence in a mammal comprising administering to the mammal a therapeutically effective amount of a synergistic combination of: (i) at least one opioid antagonist, and (ii) at least on... | 09/28/1999 |
| 5935980 | Use of pyrrolidine derivatives in the treatment of alcoholism The use of pyrrolidine derivatives of general formula (I) for treating chronic alcoholism or conditions caused by alcohol abuse is described. ##STR1##... | 08/10/1999 |
| 5925680 | Synthetic excitatory amino acids The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.... | 07/20/1999 |
| 5919781 | Use of NK-1 receptor antogonists for treating substance use disorders The present invention provides a method for the treatment or prevention of substance use disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.... | 07/06/1999 |
| 5902823 | Method for treating addiction using forskolin or extracts containing forskolin The present invention relates to the use of forskolin and of the extracts containing it for the treatment of alcohol addiction.... | 05/11/1999 |
| 5888532 | Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives Alcoholic addiction is treated by administering pyridine nucleotide phosphate derivatives having the formula represented by Formula 1: ##STR1## where y can be a second NAD group or an adenosine group and x can be 1, 2, or 3.... | 03/30/1999 |
| 5886028 | Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse Methods and compounds for inhibiting aldehyde dehydrogenase are disclosed. The compounds are useful as pharmaceutical compositions in methods for therapeutically treating alcohol consumption in a human.... | 03/23/1999 |
| 5882671 | Anxiolytic agents The present invention provides a method of treating anxiety and related disorders using an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors.... | 03/16/1999 |
| 5834477 | Opiate analgesic formulation with improved safety An opiate analgesic drug formulation which induces minimal respiratory dession is provided which contains a homogeneous mixture of an opiate agonist drug component and an opiate antagonist drug component in an aqueous medium, the opiate agonist component... | 11/10/1998 |
| 5824684 | Method for treating drug and alcohol addiction A method for treating treating drug and alcohol addiction comprising administering to a human suffering from such addiction an effective amount of an acetylcholine esterase reactivator.... | 10/20/1998 |
| 5816260 | Method for treating substance abuse withdrawal This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-meth... | 10/06/1998 |
